09 Nov 2017 Governance

Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’

Since November 2017 Leukaemia UK is the new name for the Elimination of Leukaemia Fund.

For the last four decades, Leukaemia UK has been making a difference to those living with blood cancer. We fund emotional support, pay for new hospital facilities, offer critical financial help and fund innovative research into better care and treatments for blood cancers.

We have used this, our 40th year, to review our work and achievements to develop a new strategy and vision for the future.

We want to increase our impact by supporting more families affected by blood cancer and by working with more hospitals around the UK.

Now feels like a good time to change our name from the Elimination of Leukaemia Fund to Leukaemia UK to reflect this ambition. We still hold tight to the founding principles of this charity which are:

  • to improve care and support for people living with blood cancer
  • to fund innovative research to find kinder, more effective ways of treating blood cancer

We have been fortunate to benefit from free consultancy from Frontera, a creative digital agency. The company has helped us develop a new name, logo and brand, at no cost to our supporters.

This new name encompasses our work as a leading blood cancer charity working for a blood cancer cure and improved care.  Our work will remain the same, covering all blood cancers and related disorders.

Our name change won’t affect our charity registration number, office address, bank details and company numbers. For those who donate to us through payroll giving, standing order or direct debit, you won’t need to change anything.

We remain completely reliant on voluntary donations to keep our charity and its important work running. Thank you for your generous support and for being part of our exciting journey.

Find out more about:

 

Related posts

Leukaemia UK research paves the way for personalised lymphoma treatment

19 June 2023

Leukaemia UK research paves the way for personalised lymphoma treatment

Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

25 November 2025

Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl

Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…

The latest developments and our response

26 January 2026

The latest developments and our response

The government is set to launch the National Cancer Plan for England on 4th February. We are urging policymakers to ensure it delivers meaningful change specifically for people with leukaemia….

Myelofibrosis: Finding new ways to treat patients

11 January 2019

Myelofibrosis: Finding new ways to treat patients

Dr Edwin Chen, University of Leeds and John Goldman Fellow